JMIP

Sottotitolo
Studio esplorativo di fase II di pemetrexed e cisplatino come chemioterapia pre-operatoria nel trattamento del carcinoma polmonare non a piccole cellule non squamoso allo stadio IIIAN2.

Disegno Studio
Prospettico non randomizzato

Centro
Multicentrico

Anno di inizio
2010

Ruolo di Ugo Pastorino
Principal Investigator

Numero di pazienti
7

Stato
Ongoing

Funding Agencies
Eli Lilly

---

Sinossi

Individual response to chemotherapy is the result of complex interactions between the administrated drugs, the host and tumor genetics, and the environment. To get a better understanding of these interactions, this exploratory trial is designed to evaluate the efficacy and safety of permetrexed-cisplatin as preoperative therapy in patients with stage IIIAN2 nonsquamous non-small cell lung cancer (NSCLC) and to determine the usefulness and/or efficacy. The neoadjuvant setting provides a unique opportunity to obtain the tumor tissue needed for translational research (collected both before and after chemotherapy).